New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
On January 10, 2022, Idorsia announced the FDA approval of Quviviq (daridorexant), for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
Download PDF
Return to publications
